Symbols

MPLT

MapLight Therapeutics·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About MPLT

Maplight Therapeutics, Inc.

A clinical-stage biopharmaceutical company focused on central nervous system diseases

Industry

Pharmaceutical

Established Date

Listing Date

10/27/2025

Exchange

NASDAQ Stock Exchange

Full-time Employees

133

Fiscal Year Ends

12-31

Website

www.maplightrx.com

Security Type

Common stock

Office address

800 Chesapeake Drive Redwood City California 94063

Business

Introduction

MapLight Therapeutics, Inc., was incorporated under the laws of the State of Delaware in November 2018. The company is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system diseases. Its lead drug candidate, ML-007C-MA, is a fixed-dose compound muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis and is currently in Phase 2 trials. The company is also developing ML-004 for the treatment of autism spectrum disorder social communication disorder.

Company Financials

EPS

MPLT has released its 2025 Q4 earnings. EPS was reported at -2.47, versus the expected -0.96, missing expectations. The chart below visualizes how MPLT has performed over recent quarters, highlighting trends in earnings surprises.